Research library

B

grade

A biomarker-guided treatment strategy can lead to hormonal control in nearly 80% of patients with acromegaly, suggesting a shift towards precision medicine in managing this condition.

80% of patients achieved hormonal control with biomarker-guided treatment.

summary

B

grade

Tirzepatide may reduce HbA1c in patients with pasireotide-induced hyperglycemia, but further research is necessary to confirm its effectiveness.

HbA1c decreased from 7.7% to 6.3% after switching to tirzepatide.

summary

B

grade

Tirzepatide may help manage hyperglycemia in patients treated with pasireotide, as evidenced by a decrease in HbA1c from 7.7% to 6.3%. Further research is needed to confirm these findings.

HbA1c decreased from 7.7% to 6.3%.

summary

B

grade

Pasireotide treatment in this infant with congenital hyperinsulinism did not improve glycemic control and may have worsened glycemic variability.

Not reported in abstract.

summary

B

grade

Long-term use of somatostatin analogs may help stabilize patients with occult ectopic ACTH syndrome until surgical intervention can occur.

Not reported in abstract.

summary

A

grade

Switching patients with biochemically controlled acromegaly from injected SRLs to once-daily oral paltusotine was associated with a significant reduction in the frequency of symptom exacerbations.

6.2% (1.6%) of days with symptom exacerbations after switching to paltusotine, n=22, p<0.0001.

summary

A

grade

Paltusotine shows a dose-dependent pharmacokinetic profile and safety in healthy adults, but the small sample size and short duration of the study limit the conclusions about its clinical utility.

Elimination half-life (t_1/2) was 24-28 h.

summary

D

grade

Salivary biomarkers may provide a non-invasive method for assessing endocrine and metabolic disorders, but standardization and validation are crucial for their clinical use.

Not reported in abstract.

summary

A

grade

Pasireotide shows rapid absorption and sustained release in male volunteers with chronic kidney disease and hepatitis B/C, but the clinical implications of these findings are not yet clear.

Maximal concentration at 0.5 h after SC injection(s) of pasireotide (300-900 µg).

summary

D

grade

Pasireotide may restore glucose levels in some insulinoma patients, but its effectiveness varies, especially in aggressive cases.

Seven patients (41%) had complete resolution.

summary

B

grade

GH responsiveness to CRH may help identify a unique subset of tumors in acromegaly, characterized by larger size and reduced hormone secretion capacity.

Not reported in abstract.

summary

B

grade

Pregnancy in women with acromegaly can be managed with careful consideration of treatment strategies, and most pregnancies report favorable fetal outcomes.

Symptom worsening occurred in 16.7-40%.

summary

B

grade

Multi-omics profiling can inform treatment decisions in desmoplastic small round cell tumor, with a 62% disease control rate observed in patients receiving recommended therapies.

62% disease control rate among patients receiving recommended therapies.

summary

C

grade

Dio3 expression is essential for establishing the period of circannual timing in Djungarian hamsters, but findings may not directly apply to humans.

Not reported in abstract.

summary

B

grade

This study highlights a prevalence of acromegaly in Qatar at 1.90 per 100,000, with over half of patients experiencing persistent disease despite surgery.

1.90 per 100,000 (95% CI: 1.41–2.39)

summary

D

grade

Pasireotide and Levoketoconazole can reduce cortisol levels in Cushing’s disease, but the variability in outcomes suggests further research is needed to refine treatment strategies.

Pasireotide showed a mean difference of -331 (95% CI: -1.75e+03, 1.09e+03) in 24-hour urinary free cortisol reduction.

summary

B

grade

ACTH-secreting macroadenomas can lead to severe systemic disease and require lifelong follow-up after treatment.

Not reported in abstract.

summary

B

grade

Pasireotide induces the expression of autophagy-related proteins in cancer cells, but the clinical relevance of these findings is unclear without further studies.

Not reported in abstract.

summary

A

grade

Octreotide and pasireotide may reduce total kidney volume in the short term, while lanreotide may show benefits over a longer period, but the clinical significance of these findings is unclear.

At 6 months or 1 year, octreotide (MD: -3.7, 95%CI: -4.3 to -3.2) and pasireotide (-5.0, -8.2 to -1.8) were associated with TKV reduction compared with placebo.

summary

B

grade

The study suggests that ex vivo drug sensitivity testing in patient-derived cultures may help predict responses to treatments like pasireotide in acromegaly, but findings are based on a small sample.

Median cell viability reduction of 84-86%, p<0.05.

summary

A

grade

Pasireotide treatment for acromegaly showed a 50% normalization rate of IGF-1 and a significant reduction in tumor size, but also increased HbA1c and diabetes incidence.

Mean tumor diameter decreased by -3.26 mm (95% CI -4.56 to -1.95; p<0.001) after 12 months.

summary

B

grade

Pasireotide may help normalize IGF-1 levels and resolve headaches in patients with treatment-resistant acromegaly, but this is based on a single case report.

Not reported in abstract.

summary

B

grade

The cost-effectiveness of pasireotide LAR compared to pegvisomant remains inconclusive, with some studies favoring pegvisomant while others support pasireotide LAR as a cost-effective alternative.

Not reported in abstract.

summary

B

grade

Pasireotide may help normalize IGF-1 levels and resolve headaches in patients with treatment-resistant acromegaly, but this is based on a single case report.

Not reported in abstract.

summary

D

grade

Evidence on the cost-effectiveness of pasireotide LAR compared to pegvisomant is inconclusive, with some studies favoring pegvisomant and others supporting pasireotide LAR.

Not reported in abstract.

summary